These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10719012)

  • 1. Management of cytomegalovirus infection after liver transplantation.
    Sampathkumar P; Paya CV
    Liver Transpl; 2000 Mar; 6(2):144-56. PubMed ID: 10719012
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of cytomegalovirus disease with 9-(1,3-dihydroxy-2-propoxymethyl guanine).
    de Hemptinne B; Lamy ME; Salizzoni M; Cornu C; Mostin J; Fevery J; De Groote V; Otte JB
    Transplant Proc; 1988 Feb; 20(1 Suppl 1):652-5. PubMed ID: 2831645
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus infections and liver transplantation: an overview.
    Balfour HH; Heussner RC
    Transplant Proc; 1993 Apr; 25(2):2012-3. PubMed ID: 8385830
    [No Abstract]   [Full Text] [Related]  

  • 4. [The prevention and treatment of cytomegalovirus infection after liver transplantation].
    Zheng SS; Jiang ZJ; Xu X; Liang TB; Wang WL; Shen Y; Zhang M; Lu AW
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):584-6. PubMed ID: 15938930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus disease after liver transplantation: diagnostics and therapy.
    Wiens M; Schmidt CA; Lohmann R; Oettle H; Blumhardt G; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2673-4. PubMed ID: 8395108
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of cytomegalovirus infection and disease after solid-organ transplantation.
    van der Bij W; Speich R
    Clin Infect Dis; 2001 Jul; 33 Suppl 1():S32-7. PubMed ID: 11389520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
    Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
    Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
    Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
    Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
    Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic cytomegalovirus management strategies.
    Martin M
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):23-7. PubMed ID: 7482812
    [No Abstract]   [Full Text] [Related]  

  • 11. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
    Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and prevention of cytomegalovirus in renal transplant patients: weighing the evidence.
    Hakkert A; Dykeman-Sharpe J
    CANNT J; 2003; 13(3):69-73; quiz 74-5. PubMed ID: 14596201
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
    Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
    J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
    Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Remission of severe disease induced by CMV and lymphoproliferative post-transplant disease after changing the immunosuppressive regime].
    Gómez E; Melón S; Fresno MF; Tricas L; Navascués R; de Oña M; Herreros M; Alvarez Grande J
    Nefrologia; 2002; 22(6):574-81. PubMed ID: 12516292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late cytomegalovirus disease following liver transplantation.
    Shibolet O; Ilan Y; Kalish Y; Safadi R; Ashur Y; Eid A; Shouval D; Wolf D
    Transpl Int; 2003 Dec; 16(12):861-5. PubMed ID: 12904846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.